MAPT and Alzheimer disease: On top of that, PKC activation also inhibits glycogen synthase kinase 3 (GSK3), the main kinase involved in tau phosphorylation, providing yet another confluence between PKC pathways and AD pathology [151] (Figure 5 (23,24,14)).